SAB Biotherapeutics, Inc.
SABS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | 0.01 | -0.08 |
| FCF Yield | -26.68% | -88.54% | -61.70% | -27.31% |
| EV / EBITDA | 0.14 | -2.07 | -3.17 | -2.93 |
| Quality | ||||
| ROIC | -7.30% | -45.52% | -36.46% | -27.03% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -2.44 | 0.71 | 1.50 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | -69.63% | -73.85% | -69.00% | -61.90% |
| Free Cash Flow Growth | 60.53% | -85.76% | 18.67% | -49.99% |
| Safety | ||||
| Net Debt / EBITDA | 1.83 | -0.30 | -0.26 | 0.40 |
| Interest Coverage | 292.87 | -151.25 | -154.85 | -141.22 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -287.12 | -291.45 | 90.55 |